Structure Therapeutics Inc. - Depositary Receipt (Common Stock)
US ˙ NasdaqGM ˙ US86366E1064

SecurityGPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)
InstitutionDeep Track Capital, LP
Latest Disclosed Ownership12,335,346 shares
Ownership 5.95%
Deep Track Capital, LP ownership in GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)

2026-02-13 - Deep Track Capital, LP has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 12,335,346 shares of Structure Therapeutics Inc. - Depositary Receipt (Common Stock) (US:GPCR). This represents 5.95 percent ownership of the company. In their previous filing dated 2025-11-14 , Deep Track Capital, LP had reported owning 12,647,433 shares, indicating a decrease of -2.47 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2026-02-13 2026-02-13 13G/A 12,647,433 12,335,346 -2.47 5.95 -18.72
2025-11-14 2025-11-14 13G/A 15,401,751 12,647,433 -17.88 7.32 -17.94
2025-08-14 2025-08-14 13G/A 12,300,000 15,401,751 25.22 8.92 24.76
2025-05-15 2025-05-15 13G/A 9,000,000 12,300,000 36.67 7.15 36.45
2025-01-13 2025-01-13 13G 900,000 9,000,000 900.00 5.24 693.94
2024-02-14 2024-02-14 13G/A 7,940,346 900,000 -88.67 0.66 -91.33
2023-02-03 2023-02-03 13G 7,940,346 7.61

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 4,279,848 168,066 4.09 206,289 -27.86 3.3688
2026-02-13 2025-12-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 4,111,782 -104,029 -2.47 285,974 142.26 5.0987
2025-11-14 2025-09-30 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 4,215,811 -918,106 -17.88 118,043 10.86 3.2943
2025-08-14 2025-06-30 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 5,133,917 1,033,917 25.22 106,477 50.03 3.4147
2025-05-15 2025-03-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 4,100,000 1,300,000 46.43 70,971 -6.54 2.2982
2025-02-14 2024-12-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 2,800,000 1,579,492 129.41 75,936 41.76 2.8323
2024-11-14 2024-09-30 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 1,220,508 270,508 28.47 53,568 43.59 1.6991
2024-08-14 2024-06-30 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 950,000 909,863 2,266.89 37,306 2,068.95 1.1135
2024-05-15 2024-03-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 40,137 -259,863 -86.62 1,720 -85.93 0.0493
2024-02-14 2023-12-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 300,000 -1,615,000 -84.33 12,228 -87.34 0.4084
2023-11-14 2023-09-30 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 1,915,000 -731,782 -27.65 96,554 -12.24 3.7268
2023-09-06 2023-06-30 13F/A-1 STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 2,646,782 0 0.00 110,027 74.74 5.0932
2023-08-14 2023-06-30 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 2,646,782 0 110,027 5.0932
2023-05-15 2023-03-31 13F STRUCTURE THERAPEUTICS SPONSORED ADS 86366E106 2,646,782 2,646,782 62,967 2.5861
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.